Guideline Recommendations for the Management of Allergic Conjunctivitis

First‑Line Conservative and Pharmacologic Measures

Initiate therapy with topical antihistamine‑mast cell stabilizer combination drops; these agents are more effective than older single‑mechanism drugs for both acute flare‑ups and chronic maintenance (American Academy of Ophthalmology)【1】.
Implement environmental control strategies—hand hygiene, hypoallergenic bedding, frequent laundering of clothing, nightly showering, and use of sunglasses—to reduce allergen exposure【3】.
Apply cool compresses and refrigerated preservative‑free artificial tears to dilute ocular surface allergens and inflammatory mediators【1】.
Prefer dual‑action topical agents (antihistamine + mast cell stabilizer) for symptomatic relief in acute and chronic disease【3】.

Escalate to a brief (1–2 week) course of low‑potency topical corticosteroids when first‑line measures fail to control symptoms【2】.
Monitor patients receiving corticosteroids with baseline and periodic intra‑ocular pressure checks and pupillary dilation to detect steroid‑induced glaucoma or cataract, especially with repeated or prolonged use【2】.

Use topical cyclosporine 0.05 % at least four times daily in severe or refractory conjunctivitis; it helps prevent seasonal recurrences【1】.
Consider topical tacrolimus for individuals who have not responded to corticosteroids, cyclosporine, or conventional antiallergy drops【4】.
Cyclosporine 0.1 % is FDA‑approved for vernal keratoconjunctivitis (VKC) in both children and adults, providing a steroid‑sparing option【4】.

Oral antihistamines can exacerbate dry‑eye symptoms and compromise the tear film, potentially worsening allergic conjunctivitis; if needed, they should be combined with cooled preservative‑free artificial tears【3】.
Punctal plugs should be avoided because they impede clearance of allergens and inflammatory mediators and carry a risk of extrusion and canalicular complications【3】.
Chronic use of over‑the‑counter vasoconstrictor eye drops may lead to rebound vasodilation after discontinuation【3】.

Allergic conjunctivitis and atopic disease are linked to keratoconus progression; adequate allergy control and avoidance of eye rubbing are essential to limit ectasia advancement【2】.
Prior to corneal cross‑linking, vernal and atopic keratoconjunctivitis should be well‑controlled to reduce the risk of sterile keratitis【4】.
Tacrolimus and cyclosporine may increase susceptibility to herpes simplex keratitis; clinicians should monitor for viral infection signs【2】.
Rarely, tacrolimus and pimecrolimus have been associated with skin cancer or lymphoma; vigilance is advised【2】.

Acute exacerbations – Topical corticosteroids are usually required (strong recommendation) to achieve rapid symptom control【4】.
Maintenance therapy – Topical cyclosporine 0.1 % is FDA‑approved and enables reduction of steroid exposure【4】.
Refractory disease – Supratarsal corticosteroid injection is an option for sight‑threatening cases unresponsive to topical treatment【4】.

Eyelid involvement – Treat with pimecrolimus 1 % cream or tacrolimus ointment (0.03 % for children, 0.03 %–0.1 % for adults)【4】.
Systemic therapy – Consider montelukast, aspirin, or oral T‑cell inhibitors only when topical measures fail; this is a discretionary recommendation with insufficient supporting evidence【4】.

Subcutaneous or sublingual immunotherapy can be beneficial for patients whose disease remains uncontrolled with topical agents, though cost, long‑term commitment, and anaphylaxis risk limit widespread use【3】.
Intralymphatic immunotherapy offers short‑term improvement, but its efficacy beyond one year remains uncertain【1】.